trial

"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"

NCTId NCT04641780
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 300 (estimated)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
300 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2019-08-17
Primary completion
2023-06
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

1 total
Makati City, Philippines

Facts & assertions

4 sourced
Enrollment
300
Phase
NA
Primary Completion Date
2023-06
Status
UNKNOWN
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Major Depressive Disorder
indication